- Home
- NODK vs ITOS Comparison
NODK vs ITOS Comparison
Compare NODK & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- ITOS
- Stock Information
- Founded
- NODK 1946
- ITOS 2011
- Country
- NODK United States
- ITOS United States
- Employees
- NODK N/A
- ITOS N/A
- Industry
- NODK Property-Casualty Insurers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- ITOS Health Care
- Exchange
- NODK Nasdaq
- ITOS Nasdaq
- Market Cap
- NODK 265.4M
- ITOS 381.2M
- IPO Year
- NODK 2017
- ITOS 2020
- Fundamental
- Price
- NODK $13.23
- ITOS $10.34
- Analyst Decision
- NODK
- ITOS Hold
- Analyst Count
- NODK 0
- ITOS 6
- Target Price
- NODK N/A
- ITOS $10.60
- AVG Volume (30 Days)
- NODK 17.2K
- ITOS 793.1K
- Earning Date
- NODK 08-07-2025
- ITOS 08-07-2025
- Dividend Yield
- NODK N/A
- ITOS N/A
- EPS Growth
- NODK N/A
- ITOS N/A
- EPS
- NODK N/A
- ITOS N/A
- Revenue
- NODK $322,139,000.00
- ITOS $35,000,000.00
- Revenue This Year
- NODK N/A
- ITOS N/A
- Revenue Next Year
- NODK N/A
- ITOS N/A
- P/E Ratio
- NODK $44.86
- ITOS N/A
- Revenue Growth
- NODK 3.15
- ITOS 177.89
- 52 Week Low
- NODK $12.01
- ITOS $4.80
- 52 Week High
- NODK $17.24
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- NODK 55.81
- ITOS 66.97
- Support Level
- NODK $12.76
- ITOS $10.05
- Resistance Level
- NODK $13.21
- ITOS $10.21
- Average True Range (ATR)
- NODK 0.38
- ITOS 0.13
- MACD
- NODK 0.06
- ITOS -0.06
- Stochastic Oscillator
- NODK 79.41
- ITOS 81.48
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.